Enanta Pharma (ENTA) Reports In-Line Q4 EPS

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.22), in-line with the analyst estimate of ($1.22). Revenue for the quarter came in at $23.6 million versus the consensus estimate of $26.34 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• BofA Securities Downgrades SailPoint Technologies Holdings (SAIL) to Neutral